Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | ADAMTS4 | O75173 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14862556 | 0.89 | HTT (0.43) | USP2MEN1KMT2ASMN1; SMN2NPC1 | |
| SCHEMBL17593772 | 0.89 | HTT (0.43) | USP2MEN1KMT2ASMN1; SMN2NPC1 | |
| SCHEMBL22561334 | 0.88 | ADAMTS4 (0.41) | USP2MEN1KMT2ASMN1; SMN2NPC1 | |
| SCHEMBL20733348 | 0.88 | ADAMTS4 (0.41) | USP2MEN1KMT2ASMN1; SMN2NPC1 | |
| SCHEMBL23071931 | 0.87 | USP2 (0.41) | USP2MEN1KMT2ASMN1; SMN2NPC1 | |
| SCHEMBL19361954 | 0.86 | USP2 (0.39) | USP2MEN1KMT2ASMN1; SMN2NPC1 | |
| SCHEMBL25921603 | 0.85 | SMN1; SMN2 (0.47) | USP2MEN1KMT2ASMN1; SMN2NPC1 | |
| SCHEMBL17706677 | 0.85 | MAPT (0.51) | USP2MEN1KMT2ASMN1; SMN2NPC1 | |
| SCHEMBL22508222 | 0.84 | MEN1 (0.42) | MEN1KMT2ASMN1; SMN2NPC1RAB9A | |
| SCHEMBL20149309 | 0.84 | HTT (0.50) | USP2MEN1KMT2ASMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026090173-A1 | MODIFIED SELF-IMMOLATING MOIETIES IN ANTIBODY-DRUG CONJUGATES | CODEABLE THERAPEUTICS, INCORPORATED (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20200297859-A1 | NON-LINEAR SELF-IMMOLATIVE LINKERS AND CONJUGATES THEREOF | BYONDIS B.V. (NL) | 2020-09-24 | — | — | US | disclosed |
| EP-3525826-B1 | NON-LINEAR SELF-IMMOLATIVE LINKERS AND CONJUGATES THEREOF | BYONDIS BV (NL) | 2020-07-22 | — | — | EP | disclosed |
| WO-2018069375-A1 | NON-LINEAR SELF-IMMOLATIVE LINKERS AND CONJUGATES THEREOF | SYNTHON BIOPHARMACEUTICALS B.V. (NL) | 2018-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200297859-A1 | NON-LINEAR SELF-IMMOLATIVE LINKERS AND CONJUGATES THEREOF | DLST, ADSL, LANCL1 | USP2 1470/4885MEN1 3872/4885KMT2A 2931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.